Please login to the form below

Not currently logged in
Email:
Password:

durvalumab

This page shows the latest durvalumab news and features for those working in and with pharma, biotech and healthcare.

AZ’s immuno-oncology combo fails another lung cancer trial

AZ’s immuno-oncology combo fails another lung cancer trial

Looking for the silver lining, AZ it was encouraged by the performance of PD-L1 inhibitor Imfinzi (durvalumab) as a monotherapy in a subgroup of patients in the trial, saying it

Latest news

More from news
Approximately 10 fully matching, plus 56 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    AstraZeneca will collaborate with Peregrine on a non-exclusive basis looking at the combination of bavituximab and durvalumab [MEDI4736] in solid tumours. ... No financial terms were disclosed but Mirati will conduct and fund the initial phase I/II

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics